- Home
- KALV
as of 03-18-2026 3:57pm EST
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Upcoming Earnings Alert:
Get ready for potential market movements as KalVista Pharmaceuticals Inc. (KALV) prepares to release earnings report on 25 Mar 2026.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | FRAMINGHAM |
| Market Cap: | 757.7M | IPO Year: | 2014 |
| Target Price: | $30.00 | AVG Volume (30 days): | 721.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.97 | EPS Growth: | -7.27 |
| 52 Week Low/High: | $9.83 - $19.00 | Next Earning Date: | 03-25-2026 |
| Revenue: | $50,000,000 | Revenue Growth: | 495.66% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -5.21 | Index: | N/A |
| Free Cash Flow: | -153341000.0 | FCF Growth: | N/A |
AI-Powered KALV Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of KalVista Pharmaceuticals Inc. (KALV)
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$16.08
Shares
6,693
Total Value
$107,632.81
Owned After
451,815
SEC Form 4
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$15.57
Shares
10,034
Total Value
$156,197.27
Owned After
451,815
SEC Form 4
CHIEF DEVELOPMENT OFFICER
Avg Cost/Share
$15.57
Shares
4,347
Total Value
$67,668.88
Owned After
226,701
SEC Form 4
CHIEF MEDICAL OFFICER
Avg Cost/Share
$15.57
Shares
5,354
Total Value
$83,344.65
Owned After
138,983
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$15.57
Shares
1,767
Total Value
$27,506.54
Owned After
13,762
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$15.57
Shares
3,975
Total Value
$61,878.03
Owned After
47,003
SEC Form 4
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$15.00
Shares
1,038
Total Value
$15,570.00
Owned After
451,815
SEC Form 4
CHIEF DEVELOPMENT OFFICER
Avg Cost/Share
$15.00
Shares
1,109
Total Value
$16,635.00
Owned After
226,701
SEC Form 4
CHIEF MEDICAL OFFICER
Avg Cost/Share
$15.00
Shares
1,163
Total Value
$17,445.00
Owned After
138,983
SEC Form 4
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$15.70
Shares
3,354
Total Value
$52,657.80
Owned After
451,815
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Mar 9, 2026 | Sell | $16.08 | 6,693 | $107,632.81 | 451,815 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Feb 23, 2026 | Sell | $15.57 | 10,034 | $156,197.27 | 451,815 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Feb 23, 2026 | Sell | $15.57 | 4,347 | $67,668.88 | 226,701 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Feb 23, 2026 | Sell | $15.57 | 5,354 | $83,344.65 | 138,983 | |
| Piekos Brian | KALV | Chief Financial Officer | Feb 23, 2026 | Sell | $15.57 | 1,767 | $27,506.54 | 13,762 | |
| Sweeny Nicole | KALV | Chief Commercial Officer | Feb 23, 2026 | Sell | $15.57 | 3,975 | $61,878.03 | 47,003 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Feb 18, 2026 | Sell | $15.00 | 1,038 | $15,570.00 | 451,815 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Feb 18, 2026 | Sell | $15.00 | 1,109 | $16,635.00 | 226,701 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Feb 18, 2026 | Sell | $15.00 | 1,163 | $17,445.00 | 138,983 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Feb 12, 2026 | Sell | $15.70 | 3,354 | $52,657.80 | 451,815 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 8, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLJan 8, 2026 · 100% conf.
1D
-2.98%
$15.35
Act: +6.01%
5D
-10.62%
$14.14
Act: -5.44%
20D
-18.39%
$12.91
Act: -5.82%
8-K
false 0001348911 0001348911 2026-01-08 2026-01-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2026
KALVISTA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
001-36830
20-0915291
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
200 Crossing Boulevard Framingham, Massachusetts 01702 (Address of Principal Executive Offices) (Zip Code) (857) 999-0075 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 Par Value Per Share
KALV
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On January 8, 2026, KalVista Pharmaceuticals, Inc. (the “Company”) issued a press release (the “Press Release”) announcing preliminary global net revenue of approximately $35 million and $49 million for the quarter and the eight month transition period ended December 31, 2025, respectively. The Company’s audited financial statements for the eight month transition period ended December 31, 2025, are not yet available. Accordingly, the preliminary financial information included in the Press Release is an estimate subject to the completion of the Company’s financial closing procedures and any adjustments that may result from the completion of the audit of the Company’s financial statements. The preliminary financial information may differ materially from the actual results that will be reflected in the Company’s audited financial statements when they are completed and publicly disclosed.
Item 7.01. Regulation FD Disclosure.
On January 8, 2026, the Company issued the Press Release and updated corporate presentation. Copies of the Press Release and corporate presentation issued by the Company are furnished as Exhibits 99.1 and 99.2, respectively, to this report. The information furnished with Item 2.02 and Item 7.01 of this report, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description of Exhibit
99.1
Press Release issued January 8, 2026.
99.2
Corporate Presentation.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
KALVISTA PHARMACEUTICALS, INC.
Date: January 8, 2026
By:
/s/ Brian Piekos
Brian Piekos
Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 10, 2025
Q3 2025 Earnings
8-KNov 10, 2025
8-K
false 0001348911 0001348911 2025-11-10 2025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025
KALVISTA PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-36830
20-0915291
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
200 Crossing Boulevard
Framingham, Massachusetts
01702
(Address of Principal Executive Offices)
(Zip Code) Registrant’s Telephone Number, Including Area Code: 857 999-0075
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
KALV
The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 10, 2025, KalVista Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended September 30, 2025. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report. The information furnished with Item 2.02 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number
Exhibit Description
99.1
Press release dated November 10, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KALVISTA PHARMACEUTICALS, INC.
Date: November 10, 2025
By:
/s/ Benjamin L. Palleiko
Benjamin L. Palleiko Chief Executive Officer
2025 Q2 Q2 2025 Earnings
8-K Sep 11, 2025
Q2 2025 Earnings
8-KSep 11, 2025
8-K
false 0001348911 0001348911 2025-09-11 2025-09-11 0001348911 dei:FormerAddressMember 2025-09-11 2025-09-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2025
KALVISTA PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-36830
20-0915291
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
200 Crossing Boulevard
Framingham, Massachusetts
01702
(Address of Principal Executive Offices)
(Zip Code) Registrant’s Telephone Number, Including Area Code: 857 999-0075 55 Cambridge Parkway Suite 901E Cambridge, Massachusetts 02142 (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
KALV
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On September 11, 2025, KalVista Pharmaceuticals, Inc. (the “Company”) reported its financial results for the fiscal quarter ended July 31, 2025. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report. The information furnished with Item 2.02 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit Number
Description
99.1
Press release dated September 11, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KALVISTA PHARMACEUTICALS, INC.
Date: September 11, 2025
By:
/s/ Benjamin L. Palleiko
Benjamin L. Palleiko Chief Executive Officer
Compare KALV vs Leading Stocks
See how KALV stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KALV KalVista Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.